•  
  •  
  •  
  •  

2026-02-19 06:36:55

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Nifty Gains for the second session in a row
  • Rajasthan Government announces Excise Policy Revisions, Beneficial for Suraj Industries
  • Saatvik Green Energy Secures ₹44.1 Cr Solar Module Order
  • Transwarranty Finance Ltd receives credit facility from IDFC First Bank for Digital lending
  • HCLTech named in Forbes Canada's Best Employers 2026 list

Keywords Selected:  OralSuspension

Stock Report

  • AstraZeneca Pharma India Ltd to launch Sodium Zirconium Cyclosilicate powder in Nov 2025
  • Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL
  • Lupin Launches Rivaroxaban for Oral Suspension in the United States
  • Lupin receives approval from U.S. FDA for Rivaroxaban for Oral Suspension
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
  • ZIM Laboratories Ltd announces grant of Marketing Authorization for Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal, Europe
  • Granules India Limited Received ANDA Approval for Sildenafil for Oral Suspension
  • Strides receives USFDA approval for Sevelamer Carbonate for Oral Suspension
  • Strides receives USFDA approval for Mycophenolate Mofetil for Oral Suspension
  • Lupin launches Rufinamide Oral Suspension in the United States
  • Zydus receives tentative approval from the USFDA for Bosentan Tablets for Oral Suspension
  • Glenmark Pharmaceuticals Ltd updates on Baddi facility
  • Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension
  • Lupin Launches Sildenafil for Oral Suspension in the United States
  • Strides receives USFDA approval for Ibuprofen OTC Oral Suspension
  • Strides receives USFDA approval for Ibuprofen Oral Suspension
  • Lupin receives approval from U.S. FDA for Sildenafil for Oral Suspension
  • Strides receives USFDA approval for Oseltamivir Phosphate for Oral Suspension

Latest Post

  • Nifty Gains for the second session in a row
  • Rajasthan Government announces Excise Policy Revisions, Beneficial for Suraj Industries
  • Saatvik Green Energy Secures ₹44.1 Cr Solar Module Order
  • Transwarranty Finance Ltd receives credit facility from IDFC First Bank for Digital lending
  • HCLTech named in Forbes Canada's Best Employers 2026 list


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025